Search Results
Jun 16, 2026, 10:00 ET Silicon Labs Advances Large-Scale Matter Deployments with 200-Node Matter-over-Thread Validation Network
inventory management and enabling a smoother transition between ecosystems. Silicon Labs supports CMP across its latest wireless platforms, including MG26 and Series 3 devices, helping developers build interoperable products that span multiple wireless ecosystems.The complete Matter Large Network
More news about: Silicon Labs
Jun 16, 2026, 08:48 ET GEM Launches GEM Daily Bite Product Featuring Earthlight® Whole Food Vitamin D Nationwide at Sprouts Farmers Markets, Bringing Whole Food Nutrition to the Vitamin Aisle
formulation by a range of nutrient-dense food and functional ingredients including 187.5 mg of beta glucans (whole algae fermented beta glucan), 2 billion CFU probiotics (Bacillus coagulans MTCC 5856), 250 mg of curcumin (turmeric extract), 52 mcg of vitamin K2 (chickpea fermentation), prebiotic
More news about: PLT Health Solutions
Jun 16, 2026, 08:35 ET Foundry Nation Expands Two Scoops THC Soda Line with New Classic Cola and Cream Soda Flavors
Nation, the Minnesota-based THC beverage brand known for reimagining nostalgic soda flavors, today announced the launch of two new additions to its 10mg Two Scoops THC Soda lineup: Classic Cola and Cream Soda. The new flavors build on the success of the Two Scoops collection, which combines familiar
More news about: Foundry Nation
Jun 16, 2026, 08:00 ET ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
PRO-101 study include:Prosetin is generally safe and well-tolerated across all dose levels studied in PRO-101 (0.16 – 1.05 mg/kg/day). No clinically significant abnormalities or trends were observed on study safety assessments. Critically, no prosetin-related serious adverse events
More news about: ProJenX
Jun 16, 2026, 08:00 ET Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community
gasping syndrome) have occurred in preterm and low–birth weight neonates receiving benzyl alcohol (BA)-containing drugs.FORZINITY contains 20 mg BA/mL and is not approved for use in neonates or for IV administration.HypersensitivityReported reactions include rash, papular
More news about: Stealth BioTherapeutics Inc.
Jun 16, 2026, 07:00 ET Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
N-terminal pro-B-type natriuretic peptide (NT-proBNP), a key biomarker of heart failure. Patients in both groups received doses ranging from 25 mg to 150 mg. A total of 53 patients (20 with oHCM and 33 with nHCM) completed Part D 12-week study.Results in Patients with oHCM Patients
More news about: Edgewise Therapeutics
Jun 16, 2026, 07:00 ET DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo.The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture
More news about: Dimerix Limited
Jun 15, 2026, 21:00 ET Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
the recommended Phase III dose of 450 mg once every four weeks ("Q4W"), MHB018A delivered robust and highly compelling clinical activity across both active and chronic TED populations.Clinical Activity:Active TED (aTED) – Week 12, 450 mg Q4W, N=32
More news about: Minghui Pharmaceutical
Jun 15, 2026, 16:44 ET Le Groupe Menarini présente les résultats de l'essai clinique SENTRY de phase III sur l'association selinexor-ruxolitinib dans le traitement de la myélofibrose lors du congrès 2026 de l'Association européenne d'hématologie (EHA)
SENTRY (NCT04562389), un essai pivot de phase III, est un essai randomisé, en double aveugle et contrôlé par placebo évaluant le selinexor à 60 mg en association avec le ruxolitinib dans le traitement de première intention de la myélofibrose (MF) (n = 353), par rapport au ruxolitinib en monothérapie.
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:05 ET Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
www.fda.gov/medwatch or call 1-800-FDA-1088.Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.Please see full
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 14:45 ET Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026
cardiovascular liability with melanocortin agonists, telemetry monitoring showed no changes in heart rate, blood pressure, or QTc over 24 hours at doses up to 60 mg/kg PO. Together, these data support dual MC3R/MC4R activation as a strategy to enable meaningful weight loss with favorable weight-loss quality and limited
More news about: Kalohexis
Jun 15, 2026, 08:35 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
www.fda.gov/medwatch or call 1-800-FDA-1088.Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.Please see full
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
www.fda.gov/medwatch or call 1-800-FDA-1088.Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.Please see full
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:00 ET Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
transfusion dependence and were refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESAs). Participants received ofirnoflast 2 mg orally once daily, 5 days on / 2 days off, for up to 32 weeks. The primary endpoint was hematological improvement (HI) per IWG 2018 criteria.Ofirnoflast
More news about: Halia Therapeutics
Jun 15, 2026, 07:45 ET TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
profile and determine the recommended Phase 2 dose for solid tumors. The drug demonstrated a favorable safety profile even at the highest dose level of 1,000mg administered every two weeks. Safety and pharmacokinetic data from this trial was helpful in designing the Phase 1b segment of the planned trial in
More news about: TuHURA Biosciences, Inc.
Jun 15, 2026, 07:40 ET El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis
SENTRY (NCT04562389), un ensayo pivotal de fase 3, es un ensayo aleatorizado, doble ciego y controlado con placebo de 60 mg de selinexor en combinación con ruxolitinib en el tratamiento de primera línea de la mielofibrosis (MF) (n=353), frente a la monoterapia con ruxolitinib.
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:00 ET Il Gruppo Menarini presenta i dati dello studio di fase 3 SENTRY su selinexor più ruxolitinib nella mielofibrosi in occasione del Congresso 2026 dell'Associazione Europea di Ematologia (EHA)
uno studio clinico pivotale di fase III, è uno studio randomizzato, in doppio cieco, controllato con placebo, che valuta l'efficacia di selinexor 60 mg in associazione con ruxolitinib nel trattamento di prima linea per la mielofibrosi (MF) (n=353), rispetto alla monoterapia con ruxolitinib. Condotto
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 19:48 ET One dock, one new trick carry Christie to Bassmaster Elite Series victory at Pasquotank River/Albemarle Sound
which he felt improved his hook-up ratio, and added light drop shot weight to help it sink. A Falcon Swim Jig rod paired with a Spro Jason Christie Elite MG reel and 22-pound Sunline Shooter was his primary setup.A Booyah One Knocker Spook also produced on key keeper.Forward-facing sonar was
More news about: B.A.S.S.
Jun 14, 2026, 13:17 ET 메나리니 그룹, 2026 유럽혈액학회(EHA) 학술대회에서 골수섬유증 대상 셀리넥서 및 룩소리티닙 병용요법의 제3상 SENTRY 시험 데이터 발표
SENTRY(NCT04562389)는 중추적 제3상 임상시험으로, 1차 치료 골수섬유증(MF)(n=353) 환자를 대상으로 룩소리티닙 단독요법과 비교해 60mg 셀리넥서(selinexor)와 룩소리티닙(ruxolitinib) 병용요법을 평가하는 무작위 배정, 이중눈가림, 위약 대조 시험이다. 카리오팜 테라퓨틱스(Karyopharm Therapeutics, Inc.)가 메나리니 그룹과 협력해 수행한 SENTRY는 비장 용적 35%
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
SENTRY (NCT04562389), un ensayo fundamental de fase 3, es un ensayo aleatorizado, doble ciego, controlado con placebo de 60 mg de selinexor en combinación con ruxolitinib en la mielofibrosis de primera línea (MF) (n=353), frente a la monoterapia con ruxolitinib. Realizado por
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
O SENTRY (NCT04562389), um estudo principal de Fase 3, é um estudo randomizado, duplo-cego, controlado por placebo de 60 mg de selinexor em combinação com ruxolitinibe na linha de frente da mielofibrose (MF) (n=353), versus monoterapia com ruxolitinibe. Conduzido pela Karyopharm
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
SENTRY (NCT04562389) ist eine zulassungsrelevante Phase-3-Studie, bei der 60 mg Selinexor in Kombination mit Ruxolitinib bei Myelofibrose (MF) im Erstlinienbereich (n = 353) im Vergleich zur Monotherapie mit Ruxolitinib in einer
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
SENTRY (NCT04562389), a pivotal Phase 3 trial, is a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in frontline myelofibrosis (MF) (n=353), versus ruxolitinib monotherapy. Conducted by Karyopharm Therapeutics,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.INDICATIONS FOR JAYPIRCA (pirtobrutinib)Jaypirca
More news about: Eli Lilly and Company
Jun 13, 2026, 11:15 ET Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
evaluate a type II selective JAK2 inhibitor in patients with myelofibrosis. The trial enrolled 23 patients across five dose levels (25, 50, 75, 100, and 125 mg once daily) in its dose escalation phase. Patients had received a median of two prior therapies, and all had previously received a type I JAK2 inhibitor.
More news about: Eli Lilly and Company